View Older Stories View More Recent Stories

Sep 1, 2015 07:30AM U.S. Food and Drug Administration Accepts for Priority Review the Biologics License Application for Empliciti (elotuzumab) for the Treatment of Multiple Myeloma in Patients Who Have Received One or Mo
Aug 31, 2015 08:30AM Bristol-Myers Squibb Enters Agreement Providing Exclusive Right to Acquire Promedior, Inc. and its Novel PRM-151 in Development for Fibrotic Diseases
Aug 30, 2015 07:00PM Bristol-Myers Squibb and QIMR Berghofer Medical Research Institute Announce Worldwide Collaboration to Discover Novel Immuno-Oncology Antibodies
Aug 27, 2015 02:00AM Allied-Bristol Life Sciences Licenses Platform Technology and Lead Molecules from Yale University
Aug 24, 2015 08:15AM Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis (apixaban) at the ESC Congress 2015
Aug 13, 2015 08:00AM FDA Approves U.S. Product Labeling Update for Sprycel® (dasatinib) to Include Five-Year First-Line and Seven-Year Second-Line Efficacy and Safety Data in Chronic Myeloid Leukemia in Chronic Phase
Aug 12, 2015 04:15PM U.S. Food and Drug Administration Extends Action Date for Supplemental Biologics License Application for Opdivo (nivolumab) in Previously Untreated Advanced Melanoma
Aug 4, 2015 08:00AM Bristol-Myers Squibb and The Leukemia & Lymphoma Society Announce Charitable Donation to Support Critical Routine Testing and Awareness for Chronic Myeloid Leukemia Patients
Aug 3, 2015 09:00AM Bristol-Myers Squibb Establishes Collaborative Immuno-Oncology Rare Population Malignancy (I-O RPM) Program in the U.S.
Jul 29, 2015 07:00PM Kyowa Hakko Kirin and Bristol-Myers Squibb Announce Immuno-Oncology Clinical Collaboration Studying Mogamulizumab and Opdivo (nivolumab) in Advanced Solid Tumors in the U.S.
Jul 27, 2015 07:00AM European Medicines Agency Validates and Grants Accelerated Assessment of Marketing Authorization Application for Empliciti (elotuzumab) For the Treatment of Multiple Myeloma in Patients Who Have Recei
Jul 24, 2015 02:06PM FDA Approves Daklinza (daclatasvir) for the Treatment of Patients with Chronic Hepatitis C Genotype 3
Jul 23, 2015 07:30AM Bristol-Myers Squibb Reports Second Quarter Financial Results
Jul 23, 2015 06:30AM European Medicines Agency Validates Two Parallel Type II Variation Applications to Extend the Opdivo (nivolumab) Indication in Europe
Jul 21, 2015 02:00PM Second-Generation Investigational HIV-1 Maturation Inhibitor Demonstrates Positive New Phase IIa Results, Supporting Continued Development
Jul 21, 2015 09:00AM Bristol-Myers Squibb Receives U.S. FDA Breakthrough Therapy Designation for Investigational HIV-1 Attachment Inhibitor for Heavily Treatment-Experienced Patients
Jul 20, 2015 12:07PM European Commission Approves Nivolumab BMS, the First PD-1 Immune Checkpoint Inhibitor in Europe Proven to Extend Survival for Patients with Previously-Treated Advanced Squamous Non-Small Cell Lung Ca
Jul 20, 2015 08:00AM CheckMate -025, a Pivotal Phase III Opdivo (nivolumab) Renal Cell Cancer Trial, Stopped Early
Jul 16, 2015 09:21AM European Commission Approves Bristol-Myers Squibb’s Evotaz (atazanavir and cobicistat fixed-dose combination) for the Treatment of HIV-1 Infection in Adults
Jul 15, 2015 08:30AM MUSC and Bristol-Myers Squibb Announce Translational Research Collaboration Focused on Fibrotic Diseases
Jun 25, 2015 09:30AM Bristol-Myers Squibb Expands R&D Presence Within Hubs of World Class Science and Innovation
Jun 22, 2015 08:45AM Portola, Bristol-Myers Squibb and Pfizer Announce Full Results of Second Part of Phase 3 ANNEXA-A(TM) Study Demonstrating That Investigational Andexanet Alfa Sustained Reversal of Anticoagulant Effect
Jun 22, 2015 08:45AM Portola, Bristol-Myers Squibb and Pfizer Announce Full Results of Second Part of Phase 3 ANNEXA-A(TM) Study Demonstrating That Investigational Andexanet Alfa Sustained Reversal of Anticoagulant Effect
Jun 22, 2015 02:00AM Allied-Bristol Life Sciences Licenses Intellectual Property from Harvard University
Jun 19, 2015 11:37AM European Commission Approves Bristol-Myers Squibb’s Opdivo (nivolumab), the First and Only PD-1 Checkpoint Inhibitor Approved in Europe, for Both First-Line and Previously-Treated Advanced Melanoma
Jun 18, 2015 09:00AM Bristol-Myers Squibb to Announce Results for Second Quarter 2015 on July 23
Jun 16, 2015 04:30PM Bristol-Myers Squibb Announces Dividend
Jun 11, 2015 12:00AM Bristol-Myers Squibb Demonstrates Commitment to Hematology and Advancing Research and Development Across Multiple Blood Cancers Through Immuno-Oncology Leadership at the 20th Congress of the European
Jun 9, 2015 06:02PM New Post Hoc Analyses of Phase 3b Data Examine Treatment with Orencia (abatacept) Plus Methotrexate (MTX) in Patients with Early Moderate to Severe Rheumatoid Arthritis (RA) and Markers of Poor Progno
Jun 3, 2015 08:00AM Bristol-Myers Squibb to Present Data from 14 Abstracts on Orencia (abatacept) at the European League Against Rheumatism (EULAR) 2015 Annual Meeting
Jun 2, 2015 10:45AM Adding Investigational Agent Elotuzumab to Standard Treatment for Multiple Myeloma Significantly Reduced the Risk of Disease Progression, According to New Phase III Data from ELOQUENT-2 Trial Publishe
Jun 2, 2015 10:00AM Bristol-Myers Squibb to Take Part in Goldman Sachs 36th Annual Global Health Care Conference
Jun 1, 2015 07:44AM U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo+Yervoy Regimen in Patients with Previously Untreated Advanced Melanoma
May 31, 2015 05:35PM Opdivo (nivolumab) Demonstrates Superior Survival Compared to Standard of Care (docetaxel) for Previously-Treated Squamous Non-Small Cell Lung Cancer in Phase III Trial
May 31, 2015 02:35PM Phase III CheckMate -067 Trial Demonstrates Superior Progression-Free Survival of Opdivo+Yervoy Regimen or Opdivo Monotherapy vs. Yervoy Monotherapy in Previously Untreated Patients with Advanced Mela
May 29, 2015 02:02PM Opdivo (nivolumab) First PD-1 Inhibitor to Demonstrate Superior Overall Survival Versus Standard of Care (docetaxel) in Previously-Treated Non-Squamous Non-Small Cell Lung Cancer in Pivotal Phase III
May 29, 2015 02:02PM Phase I/II Opdivo (nivolumab) Trial Shows Bristol-Myers Squibb’s PD-1 Immune Checkpoint Inhibitor is First to Demonstrate Anti-Tumor Activity In Patients With Hepatocellular Carcinoma
May 28, 2015 02:04PM Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ASCO Highlights
May 27, 2015 08:00AM Bristol-Myers Squibb Announces the Expiration of its Cash Tender Offer
May 22, 2015 07:31AM Bristol-Myers Squibb Receives Positive CHMP Opinion in the European Union for Nivolumab (Opdivo, Nivolumab BMS) for the Treatment of Advanced Squamous Non-Small Cell Lung Cancer in Previously-Treated
May 20, 2015 09:00AM Bristol-Myers Squibb Receives Amended U.S. FDA Breakthrough Therapy Designation for Investigational Daclatasvir-based Hepatitis C Regimen
May 19, 2015 08:00AM Eric Stonestreet, of Television’s Hit Comedy, “Modern Family” Joins Forces with Bristol-Myers Squibb to Launch Ready. Raise. Rise.™ to Honor Those Affected by Cancer and Increase Awareness of
May 13, 2015 08:02AM Bristol-Myers Squibb to Present Data at 2015 American Society of Clinical Oncology (ASCO) Annual Meeting that Demonstrate the Promise of its Broad Immuno-Oncology Portfolio Across Solid Tumors and Blo
May 12, 2015 06:15PM Bristol-Myers Squibb Announces the Pricing Terms of its Cash Tender Offer For Up to $500 Million Aggregate Principal Amount of its Outstanding Debt Securities
May 12, 2015 08:00AM Bristol-Myers Squibb Announces the Early Results of its Cash Tender Offer For Up to $400 Million Aggregate Principal Amount of its Outstanding Debt Securities; Increases the Maximum Amount of the Tend
May 6, 2015 10:00AM Long-Term, 7-Year Study of Nulojix® (belatacept) Regimen Demonstrates Statistically Significant Relative Risk Reduction of Death or Graft Loss over Cyclosporine Regimen in Kidney Transplant
May 4, 2015 03:38PM Bristol-Myers Squibb to Present at Bank of America Merrill Lynch 2015 Health Care Conference
Apr 29, 2015 05:00PM U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Patients with Previously Untreated Advanced Melanoma
Apr 29, 2015 10:00AM Bristol-Myers Squibb to Take Part in Deutsche Bank Global Health Care Conference
Apr 28, 2015 07:48AM Bristol-Myers Squibb Announces Cash Tender Offer For Up to $400 Million Aggregate Principal Amount of its Outstanding Debt Securities
View More Recent Stories View Older Stories